---
document_datetime: 2025-06-04 14:39:26
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/ixchiq-epar-procedural-steps-taken-scientific-information-after-authorisation-archived_en.pdf
document_name: ixchiq-epar-procedural-steps-taken-scientific-information-after-authorisation-archived_en.pdf
version: success
processing_time: 1.2723255
conversion_datetime: 2025-12-25 10:08:50.812121
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## IXCHIQ

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                                                       | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                              |
|----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|--------------------------------------------------------------------------------------|
| II/0001              | Extension of indication to include active immunisation for the prevention of disease caused by chikungunya virus (CHIKV) in adolescents 12 years and older for Ixchiq, based on interim 6 months results from study VLA1553-321; this is a randomised, double-blinded, multicentre study to | 27/02/2025                          | 28/03/2025                                  | SmPC, Annex II and PL            | Please refer to Scientific Discussion 'Ixchiq- Procedure No. EMEA/H/C/005797/II/0001 |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|         | evaluate the immunogenicity and safety of the adult dose of VLA1553 6 months following vaccination in adolescents from 12 years to less than 18 years of age after a single immunisation. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Annex II and the Package Leaflet are updated in accordance. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI. The RMP version 2.1 has been agreed. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one   |            |     |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IB/0002 | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                                                                                                                                                                                                                                                                                                              | 28/01/2025 | n/a |